{
    "id": 28501,
    "fullName": "RALGAPA1 - NRG1",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RALGAPA1-NRG1 results from the fusion of RALGAPA1 and NRG1, which has been demonstrated to be associated with resistance to Alk inhibition in cell culture (PMID: 29636358). RALGAPA1-NRG1 has been identified in non-small cell lung carcinoma (PMID: 29636358), but has not been biochemically characterized and therefore, the effect on protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 253959,
        "geneSymbol": "RALGAPA1",
        "terms": [
            "RALGAPA1",
            "GARNL1",
            "GRIPE",
            "NEDHRIT",
            "p240",
            "RalGAPalpha1",
            "TULIP1"
        ]
    },
    "variant": "RALGAPA1 - NRG1",
    "createDate": "07/19/2018",
    "updateDate": "10/23/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 3084,
                "geneSymbol": "NRG1",
                "terms": [
                    "NRG1",
                    "ARIA",
                    "GGF",
                    "GGF2",
                    "HGL",
                    "HRG",
                    "HRG1",
                    "HRGA",
                    "MST131",
                    "MSTP131",
                    "NDF",
                    "NRG1-IT2",
                    "SMDF"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 14569,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells harboring EML4-ALK and expressing RALGAPA1-NRG1 demonstrated restored sensitivity to Xalkori (crizotinib) in culture when treatment was combined with Gilotrif (afatinib), demonstrating decreased cell proliferation and reduced phosphorylation of downstream signaling molecules (PMID: 29636358).",
            "molecularProfile": {
                "id": 30251,
                "profileName": "EML4 - ALK RALGAPA1 - NRG1"
            },
            "therapy": {
                "id": 3378,
                "therapyName": "Afatinib + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16712,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK developed resistance to treatment with Alecensa (alectinib) and was subsequently found to harbor a second fusion, RALGAPA1-NRG1 (PMID: 29636358).",
            "molecularProfile": {
                "id": 30251,
                "profileName": "EML4 - ALK RALGAPA1 - NRG1"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14561,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring EML4-ALK developed resistance to treatment with Xalkori (crizotinib) after 4.5 months and was subsequently found to harbor a second fusion, RALGAPA1-NRG1, and preclinical analysis demonstrated increased phosphorylation of ERBB3 (HER3), AKT and ERK1/2, decreased phosphorylation of SHP2, and resistance to Xalkori (crizotinib) in cells expressing RALGAPA1-NRG1 (PMID: 29636358).",
            "molecularProfile": {
                "id": 30251,
                "profileName": "EML4 - ALK RALGAPA1 - NRG1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14577,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells harboring EML4-ALK and expressing RALGAPA1-NRG1 were resistant to treatment with Xalkori (crizotinib) in culture (PMID: 29636358).",
            "molecularProfile": {
                "id": 30251,
                "profileName": "EML4 - ALK RALGAPA1 - NRG1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30250,
            "profileName": "RALGAPA1 - NRG1",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30251,
            "profileName": "EML4 - ALK RALGAPA1 - NRG1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}